Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

AstraZeneca loses second top executive as Vectura gets new CEO

June 24, 2015
Life sciences
(Reuters) – AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.
 
His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved on to become CEO of privately owned cancer drug firm Syndax.
 
An AstraZeneca spokeswoman said on Wednesday that the timing of the departures was “pure coincidence” and both men were moving on to new and different types of challenges as business leaders.
 
Vectura said Ward-Lilley would become CEO effective Oct. 1, replacing Chris Blackwell, whose departure had already been announced and who will leave the small drug company at the end of this month.
 
The move is a blow to AstraZeneca, which has identified respiratory medicine as one of its six growth businesses, alongside oncology, diabetes, the heart drug Brilinta, emerging markets and Japan.
 
AstraZeneca CEO Pascal Soriot, who took over in 2012 and successfully fought off a $118 billion takeover attempt by Pfizer last year, has sought to bolster the company’s respiratory franchise.
 
The drugmaker already boasts an established blockbuster in its inhaled treatment Symbicort, for asthma and chronic lung disease, and Soriot plans to build on that after buying Pearl Therapeutics in 2013 and Almirall’s lung drug business in 2014.
 
Vectura, whose shares traded 1 percent higher by mid-morning, said Trevor Phillips would act as interim CEO from the end of June until Ward-Lilley joined the company.
 
(Additional reporting by Roshni Menon in Bengaluru; Editing by Pravin Char)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach